An interventional study of Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules in Lung Cancers, Metaverse and Extended Reality (XR), sponsored by National Taiwan University Hospital. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-25.
Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Lung Neoplasms by National Taiwan University Hospital — 12 open to participants now, 12 under way, 1 of them phase 3. Lung Neoplasms · National Taiwan University Hospital.
Among the 46 studies in Lung Neoplasms by National Taiwan University Hospital, this one is the 17th largest by planned enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2026, is one of 16 with no phase, reaches primary completion later than 5 of the 11 other live ones, and was the 43rd registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →12 of the 46 studies in Lung Neoplasms by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 18–80
National Taiwan University Hospital · Sites in Taiwan
Ages 20–90
National Taiwan University Hospital · Sites in Taiwan
Ages 20+
National Taiwan University Hospital · Sites in Taiwan
Ages 20+ · Healthy volunteers
By country, each count listing its studies:
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 2
First in 2004; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 103 across the 20 interventional studies, 131 across the 26 observational. Of the 13 that completed or were terminated, 2 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Taiwan University Hospital is the lead sponsor of 2,617 studies on the registry; 575 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
3 of the studies in Lung Neoplasms by National Taiwan University Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07434167National Taiwan University HospitalExtended Reality (XR)-Assisted CT Localization of Pulmonary Nodules | 2026-12 |
| NCT07436598National Taiwan University Hospital3D Virtual Resection for Predicting Lung Function in VATS | 2027-06-30 |
| NCT07045610National Taiwan University HospitalPrimary Resistance Mechanisms of ALK TKIs | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 46 studies in Lung Neoplasms by National Taiwan University Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules
The objective of this study is to investigate the safety and feasibility of extended reality (XR)-assisted computed tomography (CT)-guided localization of pulmonary nodules for preoperative tumor localization. The study aims to utilize a fully developed XR system to assist physicians in performing preoperative localization of pulmonary tumors, while also optimizing the workflow and efficiency of pulmonary nodule localization in a conventional CT suite.
This study plans to enroll 30 patients at our institution who are scheduled to undergo thoracoscopic sublobar resection. The safety and feasibility of using an XR-assisted digital twin model for pulmonary nodule localization in a standard CT suite will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules
This study plans to collect approximately 30 localization cases from multiple centers within our institution. First, after patient positioning and immobilization in the computed tomography (CT) suite, a chest CT scan is performed. Imaging data are processed using semi-automatic segmentation and rapid reconstruction techniques to generate, in real time, a three-dimensional model that corresponds to the patient's current localization position. During the construction of the three-dimensional model, patients remain in a fixed position. To reduce anxiety and discomfort associated with waiting, patient education related to pulmonary nodule localization and thoracoscopic surgery is provided during this period. The educational content includes the purpose of the procedure, procedural steps, potential risks, and key points of postoperative care. Once model construction is completed, a metaverse-based XR platform is used in the same setting to overlay the digital twin model onto the patient's
Localization accuracy
Procedures in this study will be conducted in a CT room. The accuracy of XR-assisted CT-guided localization will be assessed immediately after localization by employing in-room CT to determine the needle tip position and measure the distance to the target tumor.
Time frame: Immediatedly after Extended Reality (XR)-Assisted CT-Guided Localization
Assessment of perioperative outcomes
Perioperative outcomes, including intraoperative blood loss, localization time, operative time, and the rate of localization-related complications, will be measured. We will assess whether the incorporation of the localization system leads to reductions in these parameters.
Time frame: The study assessment time frame from XR-assisted CT-guided localization to discharge is approximately 3 to 7 days.
No study locations are listed for this record.
Plan to share: No — De-identified individual participant data (IPD) collected during this study will generally not be shared with other researchers, primarily due to patient privacy considerations. However, limited access to de-identified IPD may be considered in exceptional cases upon a reasonable request.
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 9 months is below that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Taiwan University Hospital →